Merck Sees $1.11 Million Put Sweep as Bears Target $90 Strike Into 2027

May 5, 2026

By TrendSpider Editor

Merck Sees $1.11 Million Put Sweep as Bears Target $90 Strike Into 2027

Unusual options activity in Merck & Company, Inc. is drawing attention Tuesday, with a dominant bearish position accounting for the vast majority of the $1,154,808 in total premium detected across two flagged contracts. Shares of MRK are trading at $113.78, up 0.57% on the session, but the large put sweep signals that at least one trader is positioning for meaningful downside over the next year-plus. The stock currently sits well above its 52-week low of $73.31, but still trails its 52-week high of $125.14, leaving a wide range in play for options traders on both sides.

Key Drivers of the MRK Stock Move

Main Catalyst: Two unusual options contracts were flagged in MRK today, carrying a combined premium of $1,154,808. The standout trade is a PUT at the $90 strike expiring June 17, 2027, with a size of 2,200 contracts and open interest of 142% relative to existing positioning, suggesting this is fresh bearish conviction rather than a hedge on an existing position.
Bull Case: A CALL at the $100 strike expiring May 22, 2026 came in-the-money, with MRK trading at $113.78. While the contract size was modest at 32, the open interest surge of 3,200% indicates outsized activity relative to prior positioning, suggesting near-term bullish interest around a strike already deep in the money.
Bear Case: The $1,111,000 in premium behind the $90 put expiring June 2027 is the dominant story here. That strike sits roughly 21% below the current price, and the long-dated expiry gives this trade room to develop. A commitment of this size at a strike that far out of the money points to a trader expecting a sustained move lower over the next 13 months.

The forward setup for MRK is complicated by several crosscurrents. The stock has already experienced significant volatility within its 52-week range of $73.31 to $125.14, a spread of more than 70% from trough to peak. The large 2027 put could reflect broader pharmaceutical sector concerns, including drug pricing policy risk, patent cliff anxieties around key franchises, or macro headwinds weighing on large-cap healthcare. The near-term call activity, while smaller in notional terms, may reflect traders capitalizing on existing momentum as the stock holds above the $100 strike. With the put expiry extending well into mid-2027, whichever macro or company-specific catalysts emerge in the coming quarters will be central to whether this bearish bet pays off.

MRK Unusual Options Activity

Two contracts were flagged as unusual in MRK on Tuesday, May 5, 2026, totaling $1,154,808 in combined premium:

Contract 1: CALL | Strike: $100 | Expiry: May 22, 2026 | Volume: 32 | Open Interest Change: 3,200% | Status: In-the-Money | Premium: $43,808
Contract 2: PUT | Strike: $90 | Expiry: June 17, 2027 | Volume: 2,200 | Open Interest Change: 142% | Status: Out-of-the-Money | Premium: $1,111,000

The put contract accounts for approximately 96% of total flagged premium, making the bearish positioning the clear dominant signal in today's unusual activity sweep.

MRK Seasonality

May has historically been a transitional month for large-cap pharmaceutical names, often seeing positioning shifts ahead of mid-year drug approval calendars and healthcare policy updates. The decision to anchor the larger trade to a June 2027 expiry suggests the trader is looking well beyond near-term seasonal patterns and is instead focused on a longer structural thesis for MRK.

MRK Relative Performance

MRK is up 0.57% on the session at $113.78, a modest gain that nonetheless keeps the stock positioned in the upper half of its 52-week range of $73.31 to $125.14. The stock remains roughly 9% below its 52-week high of $125.14, meaning bulls have room to press toward prior highs, while bears positioning at the $90 strike are wagering on a decline of more than 20% from current levels over the next 13 months.